PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), today announced human clinical trial results showing that three distinct NEUGENE® antisense drugs entered the cerebral spinal fluid (CSF) of healthy adult male volunteers following a single 100 mg dose via intravenous (IV) or subcutaneous (subq) injections. The three drugs used were AVI-4020, targeting West Nile virus (WNV); AVI-4065, targeting Hepatitis C virus (HCV); and AVI-4126, targeting the c-myc oncogene.
